214 related articles for article (PubMed ID: 37590388)
1. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
Horiuchi K; Ikemura S; Sato T; Shimozaki K; Okamori S; Yamada Y; Yokoyama Y; Hashimoto M; Jinzaki M; Hirai I; Funakoshi T; Mizuno R; Oya M; Hirata K; Hamamoto Y; Terai H; Yasuda H; Kawada I; Soejima K; Fukunaga K
Oncologist; 2024 Jan; 29(1):e108-e117. PubMed ID: 37590388
[TBL] [Abstract][Full Text] [Related]
2. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
[TBL] [Abstract][Full Text] [Related]
3. Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer.
Petranovic M; McDermott S; Mercaldo S; Little BP; Graur A; Huang K; Fintelmann FJ; Digumarthy SR; Gainor JF
Clin Lung Cancer; 2023 Dec; 24(8):682-688.e5. PubMed ID: 37758549
[TBL] [Abstract][Full Text] [Related]
4. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
Atchley WT; Alvarez C; Saxena-Beem S; Schwartz TA; Ishizawar RC; Patel KP; Rivera MP
Chest; 2021 Aug; 160(2):731-742. PubMed ID: 33621599
[TBL] [Abstract][Full Text] [Related]
6. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
[TBL] [Abstract][Full Text] [Related]
7. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis.
Yamaguchi T; Shimizu J; Oya Y; Watanabe N; Hasegawa T; Horio Y; Inaba Y; Fujiwara Y
Thorac Cancer; 2022 Mar; 13(5):724-731. PubMed ID: 35044093
[TBL] [Abstract][Full Text] [Related]
9. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
Wong A; Riley M; Zhao S; Zimmer J; Viveiros M; Wang JG; Esguerra V; Li M; Lopez G; Kendra K; Carbone DP; He K; Alahmadi A; Kaufman J; Memmott RM; Shields PG; Brownstein J; Haglund K; Welliver M; Otterson GA; Presley CJ; Wei L; Owen DH; Ho K
J Natl Compr Canc Netw; 2023 Nov; 21(11):1164-1171.e5. PubMed ID: 37935100
[TBL] [Abstract][Full Text] [Related]
10. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Cho JY; Kim J; Lee JS; Kim YJ; Kim SH; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
Lung Cancer; 2018 Nov; 125():150-156. PubMed ID: 30429014
[TBL] [Abstract][Full Text] [Related]
11. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
12. Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis.
Wong A; Riley M; Zhao S; Wang JG; Esguerra V; Li M; Lopez G; Otterson GA; Kendra K; Presley CJ; Wei L; Owen DH; Ho K
Cancer Immunol Immunother; 2023 Jun; 72(6):1727-1735. PubMed ID: 36640189
[TBL] [Abstract][Full Text] [Related]
13. Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
Ross JA; Komoda K; Pal S; Dickter J; Salgia R; Dadwal S
Cancer Med; 2022 Jan; 11(1):21-27. PubMed ID: 34873868
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Nishiyama O; Shimizu S; Haratani K; Isomoto K; Tanizaki J; Hayashi H; Yamazaki R; Oomori T; Nishikawa Y; Sano A; Nakagawa K; Tohda Y
BMC Pulm Med; 2021 May; 21(1):155. PubMed ID: 33964920
[TBL] [Abstract][Full Text] [Related]
15. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor-induced Pneumonitis: Incidence, Clinical Characteristics, and Outcomes.
Banavasi H; Kim S; Alkassis S; Daoud A; Laktineh A; Nagasaka M; Sukari A; Soubani AO
Hematol Oncol Stem Cell Ther; 2023 Jan; 16(2):144-150. PubMed ID: 34688626
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
Zhou P; Zhao X; Wang G
Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors.
Uchida Y; Kinose D; Nagatani Y; Tanaka-Mizuno S; Nakagawa H; Fukunaga K; Yamaguchi M; Nakano Y
BMC Cancer; 2022 May; 22(1):551. PubMed ID: 35578210
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer Patients with Interstitial Lung Disease: Significance of Radiological Pleuroparenchymal Fibroelastosis.
Osaki M; Arai T; Sumikawa H; Takimoto T; Takeuchi N; Tamiya A; Okishio K; Inoue Y
Oncology; 2023; 101(5):303-312. PubMed ID: 36689929
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
